Novalgin (Metamizole Sodium Monohydrate)

Metamizole acts by non‑selectively inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins. This inhibition provides central analgesic and spasmolytic effects, leading to pain relief and a reduction in fever without engaging opioid pathways.

The dose of Novalgin is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals follow local guidelines and adjust the amount to achieve effective pain or fever control while monitoring safety.

Safety data for metamizole during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Novalgin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Compared with traditional NSAIDs, metamizole offers strong analgesic and antipyretic effects with a lower incidence of gastric irritation but carries a risk of severe blood disorders. Unlike opioids, it does not cause respiratory depression, making it a useful alternative for certain acute pain scenarios.

Novalgin injection solution should be stored below 25 °C, in its original packaging, protected from light and moisture. Avoid freezing the product, and handle it using aseptic techniques to maintain sterility before administration.

Novalgin is given by intramuscular or intravenous injection under the supervision of a healthcare professional. The route and rate of administration are selected based on the clinical situation and patient tolerance.

The most serious adverse reactions include agranulocytosis, which can lead to severe infections, and severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome. Immediate medical attention is required if signs of these conditions appear.

Novalgin is contraindicated in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with existing severe blood dyscrasias, and those with a history of severe allergic reactions to the drug. It should also be avoided in patients where the risk of agranulocytosis outweighs the therapeutic benefit.